Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Blood

Volumn 111, Issue 8, 2008, Pages 3931-3940

  Tiedt, Ralph ^a   Hao Shen, Hui ^a   Sobas, Marta A ^a,b   Looser, Renate ^a   Dirnhofer, Stephan ^c   Schwaller, Jürg ^a   Skoda, Radek C ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CRE RECOMBINASE; HEMOGLOBIN; PHOSPHOTRANSFERASE; INTEGRASE; JANUS KINASE 2; MUTANT PROTEIN; PHENYLALANINE; VALINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; GENE; GENE SEQUENCE; HEMATOPOIESIS; HUMAN; JAK2 GENE; LOXP SITE; MAJOR CLINICAL STUDY; MOUSE; MXCRE GENE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHILIA; NONHUMAN; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; SOMATIC MUTATION; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSGENIC MOUSE; VAV GENE; WILD TYPE; ANIMAL; CLONOGENIC ASSAY; ENZYMOLOGY; EXTRAMEDULLARY HEMATOPOIESIS; GENETIC RECOMBINATION; GENETICS; GRANULOCYTE; HYPERPLASIA; MEGAKARYOCYTE; METABOLISM; MYELOFIBROSIS; PATHOLOGY; THROMBOCYTHEMIA; TRANSGENE;

ANIMALS; COLONY-FORMING UNITS ASSAY; GRANULOCYTES; HEMATOPOIESIS, EXTRAMEDULLARY; HUMANS; HYPERPLASIA; INTEGRASES; JANUS KINASE 2; MEGAKARYOCYTES; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; PHENOTYPE; PHENYLALANINE; POLYCYTHEMIA VERA; RECOMBINATION, GENETIC; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSGENES; VALINE;

EID: 43249084493     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-08-107748     Document Type: Article

References (40)

1. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
2. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
5. Cazzola M, Skoda R. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90:871-874.
6. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol. 2002;30:229-236.
7. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.
8. Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland DG. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006;107:4274-4281.
9. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156-11165.
10. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS ONE. 2006;1:18.
11. Zaleskas VM, Krause DS, Lazarides K, et al. Molecular pathogenesis of polycythemia induced in mice by JAK2 V617F. Blood. 2005;106.
12. Luoh SM, Stefanich E, Solar G, et al. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Mol Cell Biol. 2000;20:507-515.
13. Lee EC, Yu D, Martinez de Velasco J, et al. A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics. 2001;73:56-65.
14. Zhang Z, Lutz B. Cre recombinase-mediated inversion using lox66 and lox71: method to introduce conditional point mutations into the CREB-binding protein. Nucleic Acids Res. 2002;30:90.
15. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. Embo J. 1998;17:5321-5333.
16. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia. 2003;17:2474-2486.
17. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocy-themia and polycythemia vera. Blood. 2006;108:1865-1867.
18. Kralovics R, Teo SS, Li S, et al. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood. 2006;108:1377-1380.
19. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood. 2003;102:1869-1871.
20. de Boer J, Williams A, Skavdis G, et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. Eur J Immunol. 2003;33:314-325.
21. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427-1429.
22. Leveen P, Carlsen M, Makowska A, et al. TGF-beta type II receptor-deficient thymocytes develop normally but demonstrate increased CD8+ proliferation in vivo. Blood. 2005;106:4234-4240.
23. Birgegard G, Wide L. Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. Br J Haematol. 1992;81:603-606.
24. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89:1194-1198.
25. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-846.
26. Dupont S, Masse A, James C, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood. 2007;110:1013-1021.
27. Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005;280:27251-27261.
28. Horikawa Y, Matsumura I, Hashimoto K, et al. Markedly reduced expression of platelet c-mpl receptor in essential thrombocythemia. Blood. 1997;90:4031-4038.
29. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med. 1998;338:572-580.
30. Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood. 1999;94:2555-2561.
31. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood. 2006; 108:3913-3915.
32. Giraldo P, Montoliu L. Size matters: use of YACs, BACs and PACs in transgenic animals. Transgenic Res. 2001;10:83-103.
33. Casanova E, Fehsenfeld S, Mantamadiotis T, et al. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis. 2001;31:37-42.
34. Zhang XM, Ng AH, Tanner JA, et al. Highly restricted expression of Cre recombinase in cerebellar Purkinje cells. Genesis. 2004;40:45-51.
35. Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94:1855-1863.
36. Almarza E, Segovia JC, Guenechea G, Gomez SG, Ramirez A, Bueren JA. Regulatory elements of the vav gene drive transgene expression in hematopoietic stem cells from adult mice. Exp Hematol. 2004;32:360-364.
37. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
38. Scott LM, Scott MA, Campbell PJ, Green AR. Progenitors homozygous for the V617F JAK2 mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. Blood. 2006;108:2435-2437.
39. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-468.
40. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111:1686-1689.